{"mainPropery":{"diseaseId":9571,"diseaseName":"Hereditary renal cell carcinoma","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9571/hereditary-renal-cell-carcinoma","synonyms":[],"synonyms-with-source":[],"identifiers":[{"identifierType":"UMLS","identifierId":"C2931352"},{"identifierType":"NCI Thesaurus","identifierId":"C39789"}]},"diseaseCategories":[{"diseaseTypeId":1,"diseaseTypeName":"Rare Cancers"}],"organizations":[],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=144700' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Hereditary renal cell carcinoma. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:4450' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/renal-cell-carcinoma' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2162,"resourceId":3371,"resourceName":"The Assistance Fund","descriptionText":"<a href='https://tafcares.org/patients/covered-diseases/' target='_blank'>The Assistance Fund</a> provides various services, including education and financial aid, to help patients with a chronic or serious illness cover the cost of FDA-approved medications. Patients must be U.S citizens or permanent residents.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[],"gardCases":[],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":51,"genericName":"Sorafenib","tradeName":"Nexavar","tradeLink":"http://www.nexavar-us.com/","manufacturer":"","sponsor":"Bayer Pharmaceutical Corporation","indication":"Treatment of patients with advanced renal cell carcinoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/rn/475207-59-1","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a607051.html"},{"productId":101,"genericName":"Aldesleukin","tradeName":"Proleukin®","tradeLink":"https://www.proleukin.com/","manufacturer":"","sponsor":"Chiron Corporation","indication":"Treatment of adults (>18 years old) with metastatic renal cell carcinoma.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/Proleukin","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a692009.html"},{"productId":482,"genericName":"Temsirolimus","tradeName":"Torisel®","tradeLink":"http://torisel.com/","manufacturer":"","sponsor":"Wyeth Pharmaceuticals, Inc.","indication":"Treatment of advanced renal cell carcinoma","drugInformationLink":"http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Torisel","medlinePlusLink":"http://www.nlm.nih.gov/medlineplus/druginfo/meds/a607071.html"}],"EncodedName":"Hereditary_renal_cell_carcinoma"}